|Bid||52.49 x 1000|
|Ask||59.75 x 800|
|Day's Range||52.04 - 54.60|
|52 Week Range||39.01 - 67.79|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.20|
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
MyoKardia, Inc. (MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy (HCM). HCM is a progressive disease in which the excessive contraction of the heart muscle and reduced ability of the left ventricle to fill can lead to the development of debilitating symptoms and cardiac dysfunction, ranging from shortness of breath and reduced exercise capacity to heart failure and sudden cardiac arrest. “The initiation of our Phase 1 clinical study of MYK-224 in healthy volunteers allows us to further expand our disease-area leadership in hypertrophic cardiomyopathy,” said June Lee, M.D., MyoKardia’s Chief Development Officer.
MyoKardia, Inc. today announced the launch of the 2nd Annual MyoSeeds™ Research Grants Program, an initiative to support original, independent research in the biology and underlying mechanisms of cardiomyopathies and precision heart disease treatment. “MyoSeeds is intended to support independent research initiatives in areas that we’ve identified as important and complementary to our internal R&D priorities,” said Robert McDowell, Ph.D., MyoKardia’s Chief Scientific Officer. MyoKardia will fund up to four awards, with each award funded up to $250,000, for the 2019-2020 MyoSeeds grants cycle.
MyoKardia (MYOK) delivered earnings and revenue surprises of -5.06% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Announces Last Patient to be Enrolled in EXPLORER-HCM Phase 3 during the Week of August 12th; Topline Data Accelerated to 2nd Quarter 2020 Topline Phase 2 Clinical Data from.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 2019 Wedbush.
SOUTH SAN FRANCISCO, Calif., July 31, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter 2019 financial and operating results on.
Patient screening has closed for the Phase 3 EXPLORER-HCM registrational clinical study to assess the effect of mavacamten in treating patients with obstructive hypertrophic cardiomyopathy (oHCM). Clinical site engagement remains high, and enrollment into the pivotal trial is expected to be completed by mid-August. MyoKardia now anticipates reporting topline data from the EXPLORER-HCM trial in the second quarter of 2020, ahead of previous guidance of the second half of 2020.
MyoKardia, Inc. (MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy (oHCM) Using a Wearable Biosensor,” in the Nature Partner Journal, Digital Medicine. This research is part of MyoKardia's efforts aimed at improving the detection, diagnosis and treatment of HCM, and holds the potential to help physicians more easily identify people who may be at risk of disease.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
While MyoKardia, Inc. (NASDAQ:MYOK) shareholders are probably generally happy, the stock hasn't had particularly good...
First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in.
MyoKardia (MYOK) delivered earnings and revenue surprises of -43.08% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 93 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the.
SOUTH SAN FRANCISCO, Calif., May 07, 2019 -- MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular.
SOUTH SAN FRANCISCO, Calif., May 02, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the.
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for Which No Targeted Medical Therapies Exist Twelve-Week.